2020 ◽  
Vol 19 (5) ◽  
pp. 360-373 ◽  
Author(s):  
Panoraia I. Siafaka ◽  
Ece Ö. Bülbül ◽  
Gökce Mutlu ◽  
Mehmet E. Okur ◽  
Ioannis D. Karantas ◽  
...  

Alzheimer's disease is a neuropathological disease with symptoms such as language problems, confusion as to place or time, loss of interest in activities, which were previously enjoyed, behavioral changes, and memory loss. Alzheimer's disease and other types of dementia affect almost 46.8 million people globally and are estimated to strike about 131.5 million people in 2050. It has been reported that Alzheimer's is the sixth main cause of mortality. The most used drugs, which are currently approved by the Food, and Drug Administration for Alzheimer’s disease are donepezil, rivastigmine, galantamine, memantine, and the combination of donepezil and memantine. However, most of the drugs present various adverse effects. Recently, the transdermal drug delivery route has gained increasing attention as an emerging tool for Alzheimer's disease management. Besides, transdermal drug delivery systems seem to provide hope for the management of various diseases, due to the advantages that they offer in comparison with oral dosage forms. Herein, the current advancements in transdermal studies with potent features to achieve better Alzheimer's disease management are presented. Many researchers have shown that the transdermal systems provide higher efficiency since the first-pass hepatic metabolism effect can be avoided and a prolonged drug release rate can be achieved. In summary, the transdermal administration of Alzheimer's drugs is an interesting and promising topic, which should be further elaborated and studied.


2021 ◽  
Vol 79 (4) ◽  
pp. 1533-1546
Author(s):  
Mithilesh Prakash ◽  
Mahmoud Abdelaziz ◽  
Linda Zhang ◽  
Bryan A. Strange ◽  
Jussi Tohka ◽  
...  

Background: Quantitatively predicting the progression of Alzheimer’s disease (AD) in an individual on a continuous scale, such as the Alzheimer’s Disease Assessment Scale-cognitive (ADAS-cog) scores, is informative for a personalized approach as opposed to qualitatively classifying the individual into a broad disease category. Objective: To evaluate the hypothesis that the multi-modal data and predictive learning models can be employed for future predicting ADAS-cog scores. Methods: Unimodal and multi-modal regression models were trained on baseline data comprised of demographics, neuroimaging, and cerebrospinal fluid based markers, and genetic factors to predict future ADAS-cog scores for 12, 24, and 36 months. We subjected the prediction models to repeated cross-validation and assessed the resulting mean absolute error (MAE) and cross-validated correlation (ρ) of the model. Results: Prediction models trained on multi-modal data outperformed the models trained on single modal data in predicting future ADAS-cog scores (MAE12, 24 & 36 months= 4.1, 4.5, and 5.0, ρ12, 24 & 36 months= 0.88, 0.82, and 0.75). Including baseline ADAS-cog scores to prediction models improved predictive performance (MAE12, 24 & 36 months= 3.5, 3.7, and 4.6, ρ12, 24 & 36 months= 0.89, 0.87, and 0.80). Conclusion: Future ADAS-cog scores were predicted which could aid clinicians in identifying those at greater risk of decline and apply interventions at an earlier disease stage and inform likely future disease progression in individuals enrolled in AD clinical trials.


2011 ◽  
Vol 7 (3) ◽  
pp. e51-e59 ◽  
Author(s):  
Freddi Segal-Gidan ◽  
Debra Cherry ◽  
Randi Jones ◽  
Bradley Williams ◽  
Linda Hewett ◽  
...  

2021 ◽  
Vol 19 (11) ◽  
pp. 126-140
Author(s):  
Zahraa S. Aaraji ◽  
Hawraa H. Abbas

Neuroimaging data analysis has attracted a great deal of attention with respect to the accurate diagnosis of Alzheimer’s disease (AD). Magnetic Resonance Imaging (MRI) scanners have thus been commonly used to study AD-related brain structural variations, providing images that demonstrate both morphometric and anatomical changes in the human brain. Deep learning algorithms have already been effectively exploited in other medical image processing applications to identify features and recognise patterns for many diseases that affect the brain and other organs; this paper extends on this to describe a novel computer aided software pipeline for the classification and early diagnosis of AD. The proposed method uses two types of three-dimensional Convolutional Neural Networks (3D CNN) to facilitate brain MRI data analysis and automatic feature extraction and classification, so that pre-processing and post-processing are utilised to normalise the MRI data and facilitate pattern recognition. The experimental results show that the proposed approach achieves 97.5%, 82.5%, and 83.75% accuracy in terms of binary classification AD vs. cognitively normal (CN), CN vs. mild cognitive impairment (MCI) and MCI vs. AD, respectively, as well as 85% accuracy for multi class-classification, based on publicly available data sets from the Alzheimer’s disease Neuroimaging Initiative (ADNI).


Sign in / Sign up

Export Citation Format

Share Document